Stock Library / BNTX

BNTX Unclassified Latest YouTube: Q2 2026 Published 2026-08-04

BNTX

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Spotify Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

BioNTech (BNTX): 80% Of This Company Is Cash. Guidance Cut, Stock UP. Is BNTX Stock a Buy?

Published 2026-08-04

Open YouTube Open Spotify Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q2 2026

2026-08-04

Podcast available

Yes

Current price

$91.35

-2.65 (-2.82%)

Trailing / Forward P/E

—

Forward: -17.98x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

-35.4%

Earnings: —

Margins

-576.6% op

Gross: 78.7% · Net: -44.6%

Balance sheet

8.80x current

Debt / Equity: 1.6

52-week range / Beta

$79.52 - $124.00

Beta: 1.28

Analyst target

$122.59

Upside: 34.2%

Cash / shareholder return

-1.87% FCF yield

Dividend yield: —

Company context

Industry: Biotechnology

Country: Germany

Employees: —

Price to book: 1.07x

Return on equity: -6.7%

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Price chart

Market context for BNTX

Competitive view

BNTX vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

BNTX latest YouTube video thumbnail

BNTX

BNTX

YouTube Spotify Podbean

Latest video

Q2 2026

Growth profile looks mature or currently muted, which can cap multiple expansion unless execution improves.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

SS&C Technologies Holdings Inc. latest YouTube video thumbnail

SS&C Technologies Holdings Inc.

SSNC

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.

Palantir Technologies latest YouTube video thumbnail

Palantir Technologies

PLTR

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Expect a more volatile ride than the market average; that can amplify upside, but drawdowns can come fast too.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

BNTX

$22.95B

BNTX

SSNC

$19.02B

SS&C Technologies Holdings Inc.

PLTR

$390.88B

Palantir Technologies

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

BNTX

—

BNTX

SSNC

22.8x

SS&C Technologies Holdings Inc.

PLTR

182.8x

Palantir Technologies

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

BNTX

-18.0x

BNTX

SSNC

10.5x

SS&C Technologies Holdings Inc.

PLTR

77.7x

Palantir Technologies

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

BNTX

-35.4%

BNTX

SSNC

10.3%

SS&C Technologies Holdings Inc.

PLTR

84.7%

Palantir Technologies

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

BNTX

—

BNTX

SSNC

34.7%

SS&C Technologies Holdings Inc.

PLTR

325.0%

Palantir Technologies

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

BNTX

-576.6%

BNTX

SSNC

24.6%

SS&C Technologies Holdings Inc.

PLTR

46.2%

Palantir Technologies

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

BNTX

78.7%

BNTX

SSNC

48.1%

SS&C Technologies Holdings Inc.

PLTR

84.1%

Palantir Technologies

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

BNTX

-44.6%

BNTX

SSNC

13.2%

SS&C Technologies Holdings Inc.

PLTR

43.7%

Palantir Technologies

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

BNTX

-6.7%

BNTX

SSNC

12.6%

SS&C Technologies Holdings Inc.

PLTR

32.6%

Palantir Technologies

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

BNTX

-1.9%

BNTX

SSNC

6.8%

SS&C Technologies Holdings Inc.

PLTR

0.5%

Palantir Technologies

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

BNTX

1.62x

BNTX

SSNC

115.90x

SS&C Technologies Holdings Inc.

PLTR

2.48x

Palantir Technologies

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

BNTX

8.80x

BNTX

SSNC

1.06x

SS&C Technologies Holdings Inc.

PLTR

6.91x

Palantir Technologies

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

BNTX

1.28

BNTX

SSNC

1.09

SS&C Technologies Holdings Inc.

PLTR

1.56

Palantir Technologies

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

BNTX

—

BNTX

SSNC

1.4%

SS&C Technologies Holdings Inc.

PLTR

—

Palantir Technologies

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

BNTX

34.2%

BNTX

SSNC

13.9%

SS&C Technologies Holdings Inc.

PLTR

14.2%

Palantir Technologies

Related research

Non-quarter videos featuring BNTX

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-04

BNTX: 80% Of BioNTech Is Cash #shorts #BNTX #stocks

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for BNTX

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-08-04

Published youtube podcast complete

BioNTech (BNTX): 80% Of This Company Is Cash. Guidance Cut, Stock UP. Is BNTX Stock a Buy?

Quarterly earnings-analysis entry for BNTX. Use the links on the right to open the video or podcast episode.

YouTube Spotify Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music